{"filings":[{"id":861160,"accession_number":"0001628280-26-040784","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2026-06-04T20:11:31+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Globus Medical shareholders approve 1M share increase to equity plan, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2021 Equity Incentive Plan, increasing authorized shares by 1,000,000 to 12,000,000.","Keith Pfeil and Robert A. Douglas re-elected as Class II directors with substantial majority support.","Deloitte & Touche LLP ratified as independent auditor for fiscal year ending December 31, 2026.","Non-binding advisory vote on 2025 executive compensation passed with 316M for vs. 5.2M against.","No other matters were submitted to stockholders at the June 3, 2026 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91790,"accession_number":"0001628280-26-032164","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q1 2026: Net sales $759.9M (+27% YoY); raises FY non-GAAP EPS guidance to $4.70-$4.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.90 (+66.6% YoY); non-GAAP diluted EPS $1.12 (+64.7% YoY).","Worldwide net sales $759.9M, up 27% as-reported; base business (ex-Nevro) up 13.2%.","FY2026 revenue guidance reaffirmed at $3.18B–$3.22B; non-GAAP EPS guidance raised to $4.70–$4.80 from $4.40–$4.50.","U.S. net sales +25% YoY; international +35.6% as-reported (+27.8% constant currency).","Operating margin expanded on manufacturing initiatives and operating leverage."],"consensus_eps_estimate":null,"consensus_eps_actual":0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":759854000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102128,"accession_number":"0001628280-26-020612","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Director John A. DeFord resigns from Globus Medical Board effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John A. DeFord, Ph.D., notified the Board of his resignation on March 23, 2026, effective immediately.","DeFord stated his decision was not a result of any disagreement with the company.","He will not seek re-election at the Annual Meeting of Stockholders scheduled for June 3, 2026.","Chairman David C. Paul thanked DeFord for his contributions, especially during the NuVasive merger.","DeFord served on the Nominating and Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102127,"accession_number":"0001628280-26-011124","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q4 revenue $826.4M (+25.7% YoY); EPS $1.03 GAAP / $1.28 non-GAAP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 worldwide net sales $826.4M, up 25.7% YoY; base business ex-Nevro up 10.6%.","GAAP diluted EPS $1.03 (vs $0.19); non-GAAP diluted EPS $1.28 (vs $0.84), up 52.1%.","Full year 2025 revenue $2,938.9M (+16.7%); GAAP EPS $3.92; non-GAAP EPS $3.98.","2026 guidance: revenue $3.18-3.22B; non-GAAP EPS raised to $4.40-4.50 from $4.30-4.40.","US Spine revenue grew 10% in Q4; Enabling Technologies grew 19% over prior-year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":3.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":2938931000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102126,"accession_number":"0001628280-26-001189","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical reports record Q4 sales $823M (+25% YoY); FY2026 guidance $3.18-3.22B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 sales ~$823.2M, +25.2% YoY; full year sales ~$2.936B, +16.5% YoY.","Base business (ex-Nevro) Q4 revenue $723.3M, +10.0% YoY, led by US Spine.","Enabling Technologies delivered best quarterly revenue performance to date.","FY2026 revenue guidance $3.18B-$3.22B; non-GAAP EPS guidance $4.30-$4.40.","Final Q4/FY2025 results expected on February 24, 2026 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":3.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":2938931000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118445,"accession_number":"0001237831-25-000029","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q3 revenue $769M (+23% YoY); raises FY2025 EPS guidance to $3.75-$3.85","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $769.0M, +22.9% YoY; base business (ex-Nevro) $669.8M (+7.0%); Nevro contributed $99.3M.","GAAP diluted EPS $0.88, up 134% YoY; non-GAAP diluted EPS $1.18, up 42.6% YoY.","FY2025 revenue guidance raised to $2.86-$2.90B; non-GAAP EPS raised to $3.75-$3.85 (prev $3.00-$3.30).","Record non-GAAP free cash flow of $213.9M in Q3; share repurchases of $40M in Q3, total $255.5M YTD.","Nevro acquisition now expected to be accretive to earnings in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":2.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":2112511000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134877,"accession_number":"0001562762-25-000198","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q2 net sales $745.3M (+18.4%); GAAP EPS $1.49, non-GAAP $0.86","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $745.3M, up 18.4% YoY (17.6% constant currency); US Spine grew 5.7% as-reported.","GAAP net income $202.8M ($1.49 diluted EPS) vs $31.7M ($0.23) a year ago; includes $110.6M bargain purchase gain.","Non-GAAP diluted EPS $0.86 vs $0.75 (+14.1%); record quarterly non-GAAP EPS.","Full-year 2025 guidance reaffirmed: revenue $2.80-2.90B; non-GAAP EPS $3.00-3.30.","Closed Nevro acquisition; net cash from ops $77.9M, non-GAAP free cash flow $31.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1343463000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134876,"accession_number":"0001562762-25-000166","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Globus Medical CEO Scavilla resigns; Pfeil named CEO; preliminary Q2 sales $745.3M (+18% YoY)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Scavilla resigned as President and CEO effective July 18, 2025 to pursue another opportunity; no disagreement cited.","Keith Pfeil, formerly COO/CFO, appointed President and CEO effective July 18, 2025; also joins Board.","Kyle Kline appointed CFO effective July 18, 2025; previously SVP of Finance.","Preliminary Q2 2025 sales ~$745.3M, up 18.4% as reported; base business ex-Nevro up 4.8% day-adjusted.","Full-year 2025 guidance reaffirmed: revenue $2.80–$2.90B, non-GAAP EPS $3.00–$3.30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151836,"accession_number":"0001562762-25-000158","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Globus Medical stockholders approve equity plan amendment, elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected four directors to three-year terms: Paul, Lemaitre, Norwalk, Rhoads.","Amendment to 2021 Equity Incentive Plan approved: 247M for, 76M against.","Ratified Deloitte & Touche as auditor with 329M votes for.","Advisory vote on executive compensation approved: 315M for, 7.6M against.","Stockholders recommended 1-year frequency for say-on-pay; Board adopts annual vote until 2031."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151835,"accession_number":"0001562762-25-000131","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Globus Medical authorizes $500M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $500M buyback of Class A common stock.","CFO cites disconnect between intrinsic value and market valuation.","Repurchases at management's discretion; no time limit, can be suspended.","Funding from cash reserves; program aligns with capital allocation strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151834,"accession_number":"0001562762-25-000114","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q1 revenue down 1.4% to $598.1M; cuts non-GAAP EPS guidance to $3.00-$3.30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $75.5M; GAAP diluted EPS $0.54 vs ($0.05) a year ago.","Non-GAAP diluted EPS $0.68, up 8.5% YoY; prior guidance $3.10-$3.40 now $3.00-$3.30.","Revenue fell 1.4% as-reported (0.8% constant currency); US up 0.2%, Intl down 7.7% as-reported.","Paid off remaining $450M debt from NuVasive merger; Q1 free cash flow $141.2M.","Company cites softer Enabling Technology deals, supply chain disruption, and timing of intl orders."],"consensus_eps_estimate":null,"consensus_eps_actual":0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":598121000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151833,"accession_number":"0001193125-25-071923","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Globus Medical completes acquisition of Nevro Corp. for $5.85/share cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed acquisition of Nevro on April 3, 2025; each Nevro share received $5.85 in cash.","Nevro stock options and RSUs canceled; RSUs converted to cash equal to Merger Consideration.","Acquisition expands Globus's addressable market opportunity to $2 billion in neuromodulation.","Nevro common stock ceased trading on NYSE as of April 3, 2025.","Globus plans to discuss merger benefits during Q1 2025 earnings call in May."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170698,"accession_number":"0001562762-25-000024","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q4 sales $657.3M (+6.6% YoY); guides 2025 with Nevro acquisition impact","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $657.3M (+6.6% as-reported, +6.9% constant currency); GAAP EPS $0.19, non-GAAP EPS $0.84.","Full-year 2024 net sales $2,519.4M (+60.6% YoY); GAAP net income $103.0M; GAAP EPS $0.75, non-GAAP EPS $3.04.","2025 stand-alone guidance: revenue $2.66-2.69B, non-GAAP EPS $3.40-3.50; with Nevro acquisition (close late Q2): revenue $2.80-2.90B, non-GAAP EPS $3.10-3.40.","Q4 non-GAAP adjusted EBITDA $196.9M (30.0% of sales); full-year operating cash flow $520.6M, free cash flow $405.2M.","CEO cites record product launches and integration progress; team executed on strategic objectives to drive value."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2519355000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170697,"accession_number":"0001193125-25-021848","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Globus Medical to acquire Nevro for $5.85/sh in all-cash deal valued at ~$250M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash transaction at $5.85/share; 27% premium to 90-day VWAP of $4.61.","Total equity value approx. $250M; expected close by late Q2 2025.","Globus Medical expects Nevro acquisition to be accretive to earnings in second year.","Globus reaffirms standalone 2025 net sales guidance $2.66-$2.69B; combined guidance $2.80-$2.90B.","Preliminary 2024 revenue: Globus $2.52B (+60.6% YoY); Nevro $408-$409M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170696,"accession_number":"0001562762-25-000006","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical prelim Q4 sales $657M (+6.6% YoY), FY24 $2.52B; guides FY25 rev $2.66-2.69B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 preliminary net sales ~$657M, up 6.6% as-reported vs Q4 2023; FY2024 ~$2.52B, up 60.6%.","FY2025 revenue guidance $2.66-2.69B; fully diluted non-GAAP EPS $3.40-$3.50.","CEO highlights record product launches and highest Enabling Technology placements post-NuVasive merger.","Full Q4 and FY2024 results to be reported on February 20, 2025 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2519355000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187670,"accession_number":"0001562762-24-000250","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q3 net sales $625.7M (+63% YoY), raises FY24 revenue and EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide net sales $625.7M, up 63.1% YoY, driven by NuVasive addition and higher spine/enabling tech sales.","GAAP diluted EPS $0.38 (vs $0.01 in Q3 2023); non-GAAP diluted EPS $0.83 (vs $0.57, +45.2%).","Non-GAAP adjusted EBITDA $193.7M, or 31.0% of net sales.","Raised FY2024 guidance: revenue $2.49-$2.50B; non-GAAP diluted EPS $2.90-$3.00 (includes $0.09 change in treatment of IPR&D).","Net cash from operations $203.7M; non-GAAP free cash flow $161.7M in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":1862062000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204146,"accession_number":"0001562762-24-000209","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Globus Medical receives FDA warning letter for ExcelsiusGPS complaint procedures","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA warning letter cites non-conformities in complaint handling, trending, risk reconciliation, and MDR reporting for the ExcelsiusGPS robotic system.","Inspection occurred Feb 15–Mar 7, 2024; company says deficiencies in response letters to the Form 483.","No safety concerns with use of the system or manufacturing process were identified.","Company has taken corrective actions and believes issues can be resolved without material financial impact.","Until resolution, additional regulatory action may be taken without further notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204145,"accession_number":"0001562762-24-000195","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q2 revenue surges 115.9% to $629.7M; GAAP net income down 45%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $629.7M, up 115.9% as-reported; GAAP net income $31.8M, down 45% YoY.","GAAP diluted EPS $0.23; non-GAAP diluted EPS $0.75, up 20% vs $0.63 prior year.","Non-GAAP adjusted EBITDA $190.4M (30.2% of sales); operating cash flow $54.3M, FCF $26.5M.","Raised FY2024 revenue guidance to $2.47B-$2.49B; non-GAAP EPS $2.80-$2.90.","Growth driven by NuVasive acquisition, spine product volume, enabling technology sales."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1236357000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220878,"accession_number":"0001562762-24-000163","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Globus Medical shareholders approve amendment to 2021 Equity Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Plan amendment approved with 244,115,224 votes for, 78,950,353 against; effective June 5, 2024.","Material features described in Proxy Statement filed April 26, 2024, incorporated by reference.","Directors elected: Davidar (263.7M for), Tobin (256.5M), Zarrilli (320.0M), Wolterman (322.5M).","Ratification of Deloitte as auditor (329.3M for) and non-binding say-on-pay approved (315.4M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220877,"accession_number":"0001562762-24-000124","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q1 net sales $606.7M (+119% YoY); raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $606.7M, up 119.3% YoY, driven by NuVasive addition and higher spine/enabling tech volumes.","GAAP net loss $7.1M (($0.05) diluted EPS); non-GAAP diluted EPS $0.72, up 36.4% from $0.53.","Non-GAAP adjusted EBITDA $166.6M, or 27.5% of net sales.","FY2024 revenue guidance raised to $2.460-2.485B; non-GAAP EPS guidance raised to $2.75-2.85.","Integration of NuVasive progressing; management cites strong surgeon and sales force retention."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":606666000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240471,"accession_number":"0001562762-24-000030","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Globus Medical Q4 net sales $616.5M (+124.6% YoY); non-GAAP EPS $0.60; reaffirms FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $616.5M, +124.6% as-reported (+123.8% constant currency); driven by NuVasive merger and organic growth.","GAAP net income $15.0M (diluted EPS $0.11) down 70% YoY due to acquisition costs; non-GAAP diluted EPS $0.60 (+2.1%).","Full year 2023 net sales $1,568.5M (+53.3%); GAAP EPS $1.07; non-GAAP EPS $2.32.","Legacy Globus organic revenue grew 10.8% in Q4 and 12.8% for full year vs prior year.","FY2024 guidance reaffirmed: net sales $2.450B-$2.475B; non-GAAP EPS $2.68-$2.70."],"consensus_eps_estimate":null,"consensus_eps_actual":1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1568476000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240470,"accession_number":"0001562762-24-000019","cik":1237831,"company_name":"GLOBUS MEDICAL INC","ticker":"GMED","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Globus Medical promotes Keith Pfeil to COO and CFO effective Feb 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Pfeil adds COO role to his CFO responsibilities; effective February 1, 2024.","Base salary raised from $414,690 to $460,000; target bonus increased from $325,000 to $600,000.","Pfeil continues reporting to CEO Dan Scavilla; has been with Globus since August 2019.","Company expects to announce Q4 and full-year 2023 results on February 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11219594553.639448,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}